Lexicon is a biopharmaceutical company focused on drug discovery. The company is dedicated to discovering and developing breakthrough treatments for human disease based on understanding how genes work to maintain health.
The company was founded in 1995 and is pioneering its proprietary gene knockout technology to develop new drugs that work in new ways to fight disease and restore health. We are utilizing our knowledge of the function of nearly 5,000 genes to identify a promising portfolio of drug targets. We are well on our way to reaching our goal to advance 10 new drug candidates into human clinical trials by the end of 2010: Lexicon's 10TO10 program.
We have advanced multiple drug candidates into human clinical trials and a broad and diverse pipeline of drug targets behind our clinical programs with many compounds and antibodies in preclinical research.
Our portfolio of validated targets is supported by experts, partners and investors to transform our vision into a commercial reality for patients around the world. An experienced in-house research and development team, multiple long-term alliances with large pharmaceutical and biotechnology companies, and a $550 million investment plan will enable our success.